ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The pharmaceutical supply-chain safety group Rx-360 has set up a working group in India about two years after establishing itself in China. The working group is led by representatives from Eli Lilly & Co., Amgen, and the Indian fine chemicals producer Hikal. With headquarters in Washington, D.C., Rx-360 was established six years ago after tainted heparin from China led to the deaths of dozens of U.S. patients. Rx-360 members had earlier complained about difficulty in attracting interest from Indian firms.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter